Novonesis started 2026 with a 7% organic sales growth and a robust adjusted EBITDA margin of 37.8% in Q1, driven by growth across all sales areas and markets. The company confirmed its 2026 outlook with expected organic sales growth of 5-7% and an EBITDA margin between 37-38%. Key highlights include strong performance in Food & Health and Planetary Health Biosolutions, successful bond issuance, and acquisition of a production facility in Thailand to support expansion. Despite global uncertainties, Novonesis remains confident in achieving its long-term growth targets through continued demand for biosolutions.
Kohl's reported a strong adjusted EPS of $1.28 for Q2, more than doubling analyst expectations due to a 43% gross margin boosted by one-time tariff refunds. However, the retailer's total revenue and comparable sales fell by 0.9%, marking the 18th con...
Royal Bank of Canada reported strong Q3 2026 results, surpassing earnings per share estimates with $3.07 versus $2.89 expected, marking a 6.23% positive surprise and continuing a streak of four quarters beating expectations. Revenue also exceeded for...
Evercore ISI increased its price target for Williams-Sonoma to $245 following a strong Q2 performance, with revenue up 6.7% to $1.96 billion and comparable sales rising 6.2%, beating expectations. The gross margin improved to 51.6%, partly due to one...
RBC Capital reaffirmed its 'Sector Perform' (hold) rating on FactSet, increasing the price target from $240 to $304 as of August 27, 2026. Despite this optimistic price target adjustment, the broader market remains cautious, with an average 'Reduce' ...
Burlington Stores reported an EPS of $2.96, significantly beating analyst estimates of $2.19, driven by strong profitability improvements and an 11% growth in total sales. Comparable store sales rose 2%, continuing positive momentum from the prior ye...
